Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma

NCT01415063 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT01415063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01415063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 4
Overall status
Unknown status
Start date
February 28, 2011
Completion date
March 31, 2014
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, rfa, tace